Concepedia

Guoliang Shao

GS

Statistics

Publications

21

Citations

2.5K

H-Index

13

Active since

2002

Affiliations

Zhejiang Cancer Hospital(Current)

Zhongshan Hospital

Sun Yat-sen University

Harbin Medical University

Zhejiang University

Guoliang Shao is an author at Zhejiang Cancer Hospital specializing in oncology, medicine, and hepatocellular carcinoma treatment.

ORCID

Publications per year

2002–2025

21

Publications

21

Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2–3 study

Zhenggang Ren, Jianming Xu, Yuxian Bai et al. · The Lancet Oncology · 2021 · 1.1K citations

, , +13

Camrelizumab in Combination with Apatinib in Patients with Advanced Hepatocellular Carcinoma (RESCUE): A Nonrandomized, Open-label, Phase II Trial

Jianming Xu, Jie Shen, Shanzhi Gu et al. · Clinical Cancer Research · 2020 · 572 citations · Full text

, , +17

Brivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma: A randomized phase III trial

Masatoshi Kudo, Guohong Han, Richard S. Finn et al. · Hepatology · 2014 · 347 citations

, , +14

Immune checkpoint inhibitors and anti-vascular endothelial growth factor antibody/tyrosine kinase inhibitors with or without transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma (CHANCE2201): a target trial emulation study

Zhi‐Cheng Jin, Jian-Jia Chen, Xiaoli Zhu et al. · EClinicalMedicine · 2024 · 143 citations · Full text

, , +17

The efficacy and safety of cadonilimab combined with lenvatinib for first-line treatment of advanced hepatocellular carcinoma (COMPASSION-08): a phase Ib/II single-arm clinical trial

Qian Qiao, Chun Han, Sisi Ye et al. · Frontiers in Immunology · 2023 · 51 citations · Full text

, , +17

1–5 of 21